Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 11, 1997, Pages 2428-2432

  Vanhove, Geertrui F ^a   Kastrissios, Helen ^b   Gries, Jean Michel ^b   Verotta, Davide ^b   Park, Kyungsoo ^b   Collier, Ann C ^c   Squires, Kathleen ^d   Sheiner, Lewis B ^b   Blaschke, Terrence F ^a,e  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0030711596     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.11.2428     Document Type: Article

References (15)

1. Beal, S. L., and L. B. Sheiner. 1991. NONMEM user's guide. NONMEM Project Group, University of California at San Francisco, San Francisco, Calif.
2. Blum, M. R., S. H. T. Liao, S. S. Good, and P. de Miranda. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85(Suppl. 2A):189-194.
3. Collier, A. C., R. W. Coombs, D. A. Schoenfeld, R. Bassett, et al. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N. Engl. J. Med. 334:1011-1017.
4. Klecker, R. W., J. M. Collins, R. C. Yarchoan, R. Thomas, N. McAtee, S. Broder, and C. E. Myers. 1988. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J. Clin. Pharmacol. 28:837-842.
5. Klecker, R. W., J. M. Collins, R. Yarchoan, R. Thomas, J. F. Jenkins, et al. 1987. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′ deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and releated diseases. Clin. Pharmacol. Ther. 41:407-412.
6. MacNab, K. A., J. Gill, L. R. Sutherland, N. De Boer Visser, and V. Church. 1993. Erratic zidovudine bioavailability in HIV seropositive patients. J. Antimicrob. Chemother. 31:421-428.
7. Matthews, S. J., R. J. Cersosimo, and M. L. Spivack. 1991. Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease. Pharmacotherapy 11:419-449.
8. Meng, T. C., M. A. Fischl, A. M. Boota, et al. 1992. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann. Intern. Med. 116:13-20.
9. Ruhnke, M., F. E. Bauer, M. Seifert, M. Trautmann, H. Hille, and P. Koeppe. 1993. Effects of standard breakfast on pharmacokinetics of oral zidovudine of patients with AIDS. Antimicrob. Agents Chemother. 3:2153-2158.
10. + T-cell counts in HIV-infected patients. Ann. Intern. Med. 124:1039-1050.
11. Unadkat, J. D., A. C. Collier, S. S. Crosby, D. Cummings, K. E. Opheim, and L. Corey. 1990. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high fat meal. AIDS 4:229-232.
12. 11a. Vanhove, G. F., J.-M. Gries, D. Verotta, L. B. Sheiner, R. Coombs, A. C. Collier, and T. F. Blaschke. 1997. Exposure-response relationships for sequinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob. Agents Chemother. 41:2433-2438.
13. Verotta, D. 1995. New approaches to self-modeling non-linear regression. In D. Z. D'Argenio (ed.), Advanced methods of pharmacokinetic and pharmacodynamic system analysis II. Plenum Press, New York, N.Y.
14. Wilde, M. I., and H. D. Langtry. 1993. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 46:515-578.
15. Williams, P. E. O., G. J. Muirhead, M. J. Madigen, A M. Mitchel, and T. Shaw. 1992. Disposition and bioavailability of the protease inhibitor, Ro 31-8959, after single doses in healthy volunteers. Br. J. Clin. Pharmacol. 34:155P-156P.